Emergence and spread of the potential variant of interest (VOI) B.1.1.519 predominantly present in Mexico.

Rodriguez-Maldonado, A. P.; Vazquez-Perez, J. A.; Cedro-Tanda, A.; Taboada, B.; Boukadida, C.; Wong-Arambula, C.; Nunez-Garcia, T. E.; Cruz-Ortiz, N.; Barrera-Badillo, G.; Hernandez-Rivas, L.; Lopez-Martinez, I.; Mendoza-Vargas, A.; Reyes-Grajeda, J. P.; Alcaraz, N.; Penaloza-Figueroa, F.; Gonzalez-Barrera, D.; Rangel-DeLeon, D.; Herrera-Montalvo, L. A.; Mejia-Nepomuceno, F.; Hernandez-Teran, A.; Mujica-Sanchez, M.; Becerril-Vargas, E.; Martinez-Orozco, J. A.; Perez-Padilla, R.; Salas-Hernandez, J.; Sanchez-Flores, A.; Isa, P.; Matias-Florentino, M.; Avila-Rios, S.; Munoz-Medina, J. E.; Grajal,

SARS-CoV-2 variants have emerged in late 2020 and there are at least three variants of concern (B.1.1.7, B.1.351, P1) reported by WHO. These variants have several substitutions in the Spike protein that affect receptor binding; they present increased transmissibility and may be associated with reduced vaccine effectiveness. In the present work, we are reporting the identification of a potential variant of interest harboring the mutations T478K, P681H, and T732A in the Spike protein, within the newly named lineage B.1.1.519, which rapidly outcompeted the preexisting variants in Mexico and has been the dominant virus in the country during the first trimester of 2021.